Level of evidence for therapeutic drug monitoring of vancomycin
Vancomycin is an antibiotic for exclusive hospital use administrated in intravenous infusion to treat systemic infections. It is mainly eliminated by kidneys and potentially nephrotoxic. Data available show that Therapeutic Drug Monitoring (TDM) of vancomycin is highly recommended. It aims to ensure...
Gespeichert in:
| Veröffentlicht in: | Therapie 2011-01, Vol.66 (1), p.29 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 29 |
| container_title | Therapie |
| container_volume | 66 |
| creator | Jelassi, Mohamed Larbi Benlmouden, Amine Lefeuvre, Sandrine Mainardi, Jean-Luc Billaud, Eliane M |
| description | Vancomycin is an antibiotic for exclusive hospital use administrated in intravenous infusion to treat systemic infections. It is mainly eliminated by kidneys and potentially nephrotoxic. Data available show that Therapeutic Drug Monitoring (TDM) of vancomycin is highly recommended. It aims to ensure efficacy and avoid resistance by maintaining trough plasma concentrations above the MIC. Secondary, vancomycine TDM may be indicated to prevent nephrotoxicity in high risk patients. TDM is often underwent at steady state (48 to 72 h after the treatment initiation) unless in case of renal impairment (24 h). While compared with intermittent administration, continuous infusion did not result in prognosis improvement; however it resulted in lower pharmacokinetic variability and better cost-efficiency. Targeted trough concentrations for intermittent infusion are between 15 and 20 mg/L (up to 25-30 mg/L for GISA). In case of continuous infusion, targets are higher (25 to 40 mg/L). |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_21466775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21466775</sourcerecordid><originalsourceid>FETCH-LOGICAL-p565-6af65a73cf2fd5bff938cecfaa60e0c9f1cdb744602745e06598dfe97259ec4e3</originalsourceid><addsrcrecordid>eNo1j8tKAzEUQLNQ2lr9BckPDGQyuUmzEim-YMBN9yWT3NtGOsmQeUD_XkRdnc3hwLlhGyGUqMCCWbO7cfwSQtbGmhVby1ppbQxs2FOLC154Jo5LDJg8csqFT2csbsB5ip6HMp94n1Occonp9OMuLvncX31M9-yW3GXEhz9u2eH15bB_r9rPt4_9c1sNoKHSjjQ403iSFKAjss3OoyfntEDhLdU-dEYpLaRRgEKD3QVCayRY9AqbLXv8zQ5z12M4DiX2rlyP_yPNN0ktRMs</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Level of evidence for therapeutic drug monitoring of vancomycin</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Jelassi, Mohamed Larbi ; Benlmouden, Amine ; Lefeuvre, Sandrine ; Mainardi, Jean-Luc ; Billaud, Eliane M</creator><creatorcontrib>Jelassi, Mohamed Larbi ; Benlmouden, Amine ; Lefeuvre, Sandrine ; Mainardi, Jean-Luc ; Billaud, Eliane M ; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique</creatorcontrib><description>Vancomycin is an antibiotic for exclusive hospital use administrated in intravenous infusion to treat systemic infections. It is mainly eliminated by kidneys and potentially nephrotoxic. Data available show that Therapeutic Drug Monitoring (TDM) of vancomycin is highly recommended. It aims to ensure efficacy and avoid resistance by maintaining trough plasma concentrations above the MIC. Secondary, vancomycine TDM may be indicated to prevent nephrotoxicity in high risk patients. TDM is often underwent at steady state (48 to 72 h after the treatment initiation) unless in case of renal impairment (24 h). While compared with intermittent administration, continuous infusion did not result in prognosis improvement; however it resulted in lower pharmacokinetic variability and better cost-efficiency. Targeted trough concentrations for intermittent infusion are between 15 and 20 mg/L (up to 25-30 mg/L for GISA). In case of continuous infusion, targets are higher (25 to 40 mg/L).</description><identifier>ISSN: 0040-5957</identifier><identifier>PMID: 21466775</identifier><language>fre</language><publisher>France</publisher><subject>Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - economics ; Anti-Bacterial Agents - pharmacokinetics ; Anti-Bacterial Agents - therapeutic use ; Bacterial Infections - drug therapy ; Bacterial Infections - economics ; Bacterial Infections - microbiology ; Dose-Response Relationship, Drug ; Drug Monitoring - methods ; Evidence-Based Medicine ; Humans ; Infusions, Intravenous ; Kidney Diseases - complications ; Kidney Diseases - metabolism ; Vancomycin - administration & dosage ; Vancomycin - adverse effects ; Vancomycin - economics ; Vancomycin - pharmacokinetics ; Vancomycin - therapeutic use</subject><ispartof>Therapie, 2011-01, Vol.66 (1), p.29</ispartof><rights>2011 Société Française de Pharmacologie et de Thérapeutique.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21466775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jelassi, Mohamed Larbi</creatorcontrib><creatorcontrib>Benlmouden, Amine</creatorcontrib><creatorcontrib>Lefeuvre, Sandrine</creatorcontrib><creatorcontrib>Mainardi, Jean-Luc</creatorcontrib><creatorcontrib>Billaud, Eliane M</creatorcontrib><creatorcontrib>Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique</creatorcontrib><title>Level of evidence for therapeutic drug monitoring of vancomycin</title><title>Therapie</title><addtitle>Therapie</addtitle><description>Vancomycin is an antibiotic for exclusive hospital use administrated in intravenous infusion to treat systemic infections. It is mainly eliminated by kidneys and potentially nephrotoxic. Data available show that Therapeutic Drug Monitoring (TDM) of vancomycin is highly recommended. It aims to ensure efficacy and avoid resistance by maintaining trough plasma concentrations above the MIC. Secondary, vancomycine TDM may be indicated to prevent nephrotoxicity in high risk patients. TDM is often underwent at steady state (48 to 72 h after the treatment initiation) unless in case of renal impairment (24 h). While compared with intermittent administration, continuous infusion did not result in prognosis improvement; however it resulted in lower pharmacokinetic variability and better cost-efficiency. Targeted trough concentrations for intermittent infusion are between 15 and 20 mg/L (up to 25-30 mg/L for GISA). In case of continuous infusion, targets are higher (25 to 40 mg/L).</description><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - economics</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - economics</subject><subject>Bacterial Infections - microbiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Monitoring - methods</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Kidney Diseases - complications</subject><subject>Kidney Diseases - metabolism</subject><subject>Vancomycin - administration & dosage</subject><subject>Vancomycin - adverse effects</subject><subject>Vancomycin - economics</subject><subject>Vancomycin - pharmacokinetics</subject><subject>Vancomycin - therapeutic use</subject><issn>0040-5957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tKAzEUQLNQ2lr9BckPDGQyuUmzEim-YMBN9yWT3NtGOsmQeUD_XkRdnc3hwLlhGyGUqMCCWbO7cfwSQtbGmhVby1ppbQxs2FOLC154Jo5LDJg8csqFT2csbsB5ip6HMp94n1Occonp9OMuLvncX31M9-yW3GXEhz9u2eH15bB_r9rPt4_9c1sNoKHSjjQ403iSFKAjss3OoyfntEDhLdU-dEYpLaRRgEKD3QVCayRY9AqbLXv8zQ5z12M4DiX2rlyP_yPNN0ktRMs</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Jelassi, Mohamed Larbi</creator><creator>Benlmouden, Amine</creator><creator>Lefeuvre, Sandrine</creator><creator>Mainardi, Jean-Luc</creator><creator>Billaud, Eliane M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201101</creationdate><title>Level of evidence for therapeutic drug monitoring of vancomycin</title><author>Jelassi, Mohamed Larbi ; Benlmouden, Amine ; Lefeuvre, Sandrine ; Mainardi, Jean-Luc ; Billaud, Eliane M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p565-6af65a73cf2fd5bff938cecfaa60e0c9f1cdb744602745e06598dfe97259ec4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - economics</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - economics</topic><topic>Bacterial Infections - microbiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Monitoring - methods</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Kidney Diseases - complications</topic><topic>Kidney Diseases - metabolism</topic><topic>Vancomycin - administration & dosage</topic><topic>Vancomycin - adverse effects</topic><topic>Vancomycin - economics</topic><topic>Vancomycin - pharmacokinetics</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jelassi, Mohamed Larbi</creatorcontrib><creatorcontrib>Benlmouden, Amine</creatorcontrib><creatorcontrib>Lefeuvre, Sandrine</creatorcontrib><creatorcontrib>Mainardi, Jean-Luc</creatorcontrib><creatorcontrib>Billaud, Eliane M</creatorcontrib><creatorcontrib>Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Therapie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jelassi, Mohamed Larbi</au><au>Benlmouden, Amine</au><au>Lefeuvre, Sandrine</au><au>Mainardi, Jean-Luc</au><au>Billaud, Eliane M</au><aucorp>Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Level of evidence for therapeutic drug monitoring of vancomycin</atitle><jtitle>Therapie</jtitle><addtitle>Therapie</addtitle><date>2011-01</date><risdate>2011</risdate><volume>66</volume><issue>1</issue><spage>29</spage><pages>29-</pages><issn>0040-5957</issn><abstract>Vancomycin is an antibiotic for exclusive hospital use administrated in intravenous infusion to treat systemic infections. It is mainly eliminated by kidneys and potentially nephrotoxic. Data available show that Therapeutic Drug Monitoring (TDM) of vancomycin is highly recommended. It aims to ensure efficacy and avoid resistance by maintaining trough plasma concentrations above the MIC. Secondary, vancomycine TDM may be indicated to prevent nephrotoxicity in high risk patients. TDM is often underwent at steady state (48 to 72 h after the treatment initiation) unless in case of renal impairment (24 h). While compared with intermittent administration, continuous infusion did not result in prognosis improvement; however it resulted in lower pharmacokinetic variability and better cost-efficiency. Targeted trough concentrations for intermittent infusion are between 15 and 20 mg/L (up to 25-30 mg/L for GISA). In case of continuous infusion, targets are higher (25 to 40 mg/L).</abstract><cop>France</cop><pmid>21466775</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-5957 |
| ispartof | Therapie, 2011-01, Vol.66 (1), p.29 |
| issn | 0040-5957 |
| language | fre |
| recordid | cdi_pubmed_primary_21466775 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - economics Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Bacterial Infections - drug therapy Bacterial Infections - economics Bacterial Infections - microbiology Dose-Response Relationship, Drug Drug Monitoring - methods Evidence-Based Medicine Humans Infusions, Intravenous Kidney Diseases - complications Kidney Diseases - metabolism Vancomycin - administration & dosage Vancomycin - adverse effects Vancomycin - economics Vancomycin - pharmacokinetics Vancomycin - therapeutic use |
| title | Level of evidence for therapeutic drug monitoring of vancomycin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Level%20of%20evidence%20for%20therapeutic%20drug%20monitoring%20of%20vancomycin&rft.jtitle=Therapie&rft.au=Jelassi,%20Mohamed%20Larbi&rft.aucorp=Groupe%20Suivi%20Therapeutique%20Pharmacologique%20de%20la%20Societe%20Francaise%20de%20Pharmacologie%20et%20de%20Therapeutique&rft.date=2011-01&rft.volume=66&rft.issue=1&rft.spage=29&rft.pages=29-&rft.issn=0040-5957&rft_id=info:doi/&rft_dat=%3Cpubmed%3E21466775%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21466775&rfr_iscdi=true |